

# Antimicrobial Stewardship in a Pediatric Hospital Lessons Learned

Marian G. Michaels, MD, MPH  
Professor of Pediatrics and Surgery  
Division of Pediatric Infectious Diseases  
Children's Hospital of Pittsburgh of UPMC

# Disclaimers

- I have no relevant conflict of interests
- I may discuss off label use of drugs or devices

# Learning Objectives

- At the end of the talk attendees should be able to:
  - Recognize the necessity for antimicrobial stewardship programs
  - Describe the essential components of ASP
  - Understand value of ASP for inpatient settings

# A story.....

- 2 year old child with leukemia is admitted to PICU with high fever, decreased BP, and respiratory distress requiring resuscitation and ventilatory support
- Vancomycin, meropenem, clindamycin, liposomal amphotericin and high dose acyclovir
- All cultures are negative
- But because "he seems better" they continue antimicrobials
- Kidney dysfunction develops
- Day 10: trach culture has MDR bacteria


# What happened?

- This is a sick child
- But doing everything isn't necessarily the right thing ....
- ...and can cause harm
- Hopefully an antimicrobial stewardship program (ASP) would help this child avoid untoward side effects...
- ....and help the hospital have less resistant microbes

# Origins of Antimicrobial Stewardship: Explosion of Antimicrobial Resistance

Selected antimicrobial-resistant pathogens associated with nosocomial ICU infections: Comparison of resistance rates in 2003 vs. 1998- 2002, NNIS system.  
Special report NNIS, AJIC 2004


- Vancomycin/enterococci
- Methicillin/*S. aureus*
- Methicillin/CNS
- 3rd Ceph/*E. coli*\*\*
- 3rd Ceph/*K. pneumoniae*\*\*
- Imipenem/*P. aeruginosa*
- Quinolone/*P. aeruginosa*
- 3rd Ceph/*P. aeruginosa*
- 3rd Ceph/*Enterobacter* spp.



Jan-Dec 2003 No. of Isolates	% increase in resistance (2003 vs 98-02*)
2048	12%
4100	11%
3336	1%
1355	0%
1068	47%
1392	15%
1825	9%
2119	20%
1411	-6%

# Here Come the Superbugs!

Medscape® [www.medscape.com](http://www.medscape.com)




# Antimicrobial Resistance hits the News: USA Today (3/6/13)

## CDC sounds alarm on deadly, untreatable superbugs

### DEADLY BACTERIA THAT DEFY DRUGS OF LAST RESORT


A new family of antibiotic-resistant bacteria, known as CRE, is raising concerns across the medical community because of its ability to cause infections that defy even the strongest antibiotics. The antibiotic resistance is spread by mobile pieces of DNA that can move between different species of bacteria, creating new, drug-defying bugs.

#### Where the organisms can infect the body



#### How a resistance gene moves between bacteria

When antibiotic-resistant bacteria are present in the body and antibiotics are introduced ...







## Briefing Room

Your Weekly Address

Speeches &amp; Remarks

Press Briefings

**Statements & Releases**

White House Schedule

Presidential Actions

Executive Orders

The White House  
Office of the Press Secretary

For Immediate Release

March 27, 2015

SHARE THIS:



TWITTER



FACEBOOK



EMAIL

# FACT SHEET: Obama Administration Releases National Action Plan to Combat Antibiotic-

## Resistance

### Slow the Emergence of Resistant Bacteria and Prevent the Spread of Resistant Infections

Judicious use of antibiotics in healthcare and agricultural settings is essential to slow the emergence of resistance and extend the useful lifetime of effective antibiotics. The CDC estimates that up to half of all human antibiotic use is unnecessary or inappropriate. The Action Plan includes activities to foster improvements in the appropriate use of antibiotics (i.e., antibiotic stewardship) by improving prescribing practices across all healthcare settings, preventing the spread of drug-resistant threats in healthcare facilities and communities, and continuing to eliminate the use of medically-important antibiotics for growth promotion in animals.

By 2020, significant outcomes in this area will include:

- Establishment of antimicrobial stewardship programs in all acute care hospitals and improved antimicrobial stewardship across all healthcare settings.
- Reduction of inappropriate antibiotic use by 50% in outpatient settings and by 20% in inpatient settings.
- Establishment of State Antibiotic Resistance (AR) Prevention (Protect) Programs in all 50 states to monitor regionally important multi-drug resistant organisms and provide feedback and technical assistance to health care facilities.
- Elimination of the use of medically-important antibiotics for growth promotion in food-producing animals.

# March 2015



# Four Core Actions to Fight Resistance

(<http://www.cdc.gov/drugresistance/pdf/4-2013-508.pdf>)

1. Prevent infections & spread of resistance
2. Track rates of resistance over time
3. Improve Antibiotic Prescribing / Antimicrobial Stewardship
4. Develop New Drugs & Diagnostic Tests

# What Can ASP DO?

## ANTIBIOTIC STEWARDSHIP IN YOUR FACILITY WILL



### DECREASE

- ANTIBIOTIC RESISTANCE
- C. DIFFICILE INFECTIONS
- COSTS

### INCREASE

- GOOD PATIENT OUTCOMES



# ASP Strategies: Inpatient Focus

- Core strategies
  - Formulary restriction and preauthorization
  - Prospective audit with intervention and feedback
- Supplemental Strategies
  - Education
  - Clinical Guidelines
  - IV to PO conversion
  - Dose optimization
  - Antimicrobial Order Forms

Newland & Hersh/PIDJ/2010

# ASP Core Strategies: PROS

- Preauthorization:
  - ↓starting unnecessary/inappropriate Abx
  - Direct control of chosen Abx use/ cost
  - Prompts review of available data at time of initiation of Abx
- Prospective audit and feedback:
  - Review when more clinical data available
  - Greater flexibility in timing of recommendation
  - Prescriber autonomy maintained
  - Can address de-escalation, duration & switch to oral Abx

Barlam et al CID 2016 IDSA Guidelines

# ASP Core strategies: Cons

- Preauthorization:
  - Only impacts “chosen Abx”
  - Real-time resource intensive
  - May delay therapy
  - Loss of prescriber autonomy
- Prospective audit and feedback:
  - Compliance voluntary
  - Typically labor -intensive
  - Requires technology support

# Antimicrobial Stewardship Program: CHP



# CHP: Then

- > 30 yrs preauthorization approval for “restricted antibiotics” by ID group
  - Not approved for children - Ex: quinolones
  - Very broad spectrum drugs - Ex: carbapenems
  - Expensive new drugs- Ex: linezolid
  - Direct towards “drugs of choice”
- Downside:
  - No tracking of antibiotic use once approved
  - Development of antimicrobial resistance
  - No formal antimicrobial stewardship program



# Antimicrobial Susceptibility Tracking



# Models of ASP:


## “Traditional Model” Includes Involvement of:

- ID Physician Leader
- Dedicated ASP Pharmacist with ID Training
- Pharmacy Director
- P&T Committee
- Infection Prevention
- Informatics
- Hospital Administration

## CHP Model Includes Involvement of:

- ID Physician Leader & Full ID Division
- Team of 7 Service-based Pharmacists
- Pharmacy Director
- P&T Committee
- Infection Prevention
- Informatics
- Hospital Administration

# PHIS Antimicrobial Analysis: 2007



# ASP AT CHP: 2008

## A Quality Assessment of a Collaborative Model of a Pediatric Antimicrobial Stewardship Program

Phuong-Tan Nguyen-Ha, PharmD,<sup>a</sup> Denise Howrie, PharmD,<sup>a</sup> Kelli Crowley, PharmD,<sup>a</sup> Carol G. Vetterly, PharmD,<sup>a</sup> William McGhee, PharmD,<sup>a</sup> Donald Berry, RPh,<sup>a</sup> Elizabeth Ferguson, PharmD,<sup>a</sup> Emily Polischuk, PharmD,<sup>a</sup> Maria Mori Brooks, PhD,<sup>b</sup> Jeffrey Goff, RPh, MS,<sup>a</sup> Terri Stillwell, MD, MPH,<sup>c</sup> Toni Darville, MD,<sup>d</sup> Ann E. Thompson, MD,<sup>e</sup> James E. Levin, MD, PhD,<sup>f,†</sup> Marian G. Michaels, MD, MPH,<sup>f,§</sup> Michael Green, MD, MPH<sup>f,§</sup>

PEDIATRICS Volume 137, number 5, May 2016



# CHP ASP: Development of Guidelines

- **Multistep process: targeted antimicrobials**
  - Review of literature
  - Small group meeting with representatives from key stakeholder groups
  - Development of “draft” guideline followed by review by full stakeholder groups, P & T Committee and Clinical Resource Management Committee
- **Approved guidelines = basis for Day 3 Audits**
- **Guidelines include:**
  - Post-op prophylaxis & antifungal use for Liver & Intestinal Tx
  - Use of ciprofloxacin & vancomycin for IBD patients
  - Use of meropenem (all CHP patient populations)
  - Empiric antimicrobial regimens for surgical infants in NICU
  - Empiric antimicrobial regimens in the CICU

# Communicating Recommendations

The screenshot shows a clinical notes application window titled "Clinical Notes". The interface includes a top navigation bar with "Normal view", "Print", and "1 minutes ago" options. A left sidebar contains a folder tree with categories like "Clinical Consents", "Discharge Summary", "Patient/Family Education", "Progress Notes", "Ancillary Service Record", "Care Coordination", "Child Life Note", "Medication Management", and "Antimicrobial Stewardship". The main content area displays a document for the period "November 21, 2014 - November 25, 2014 : 20 out of 22 documents are accessible. (Date Range) In Error Documents Filtered".


The document content is organized into sections:

- Initial antimicrobial rational:** Treatment of proven infection.
- Histories**
  - Device placement per documentation:** Central Arterial or Venous Catheters.
  - Risks in past 7 days:** Lymphopenia <1500, Renal insufficiency.
  - Hx of antimicrobial resistance:** MRSA Infection, VRE Infection, Multi-Drug Resistant GNR.
  - History of recurrent infections present
  - Notable antimicrobial allergies ertapenem
- Review/ Management**
  - Relevant antimicrobials:** Meropenem.
  - Significant cultures:**
    - Positives: Specimen Source ( Respiratory, OTHER moderate WBC ), 11/19/14, Isolate Pseudomonas, Klebsiella, S aureus.
    - Positives: Specimen Source ( Urine ), 11/19/14, Isolate Pseudomonas, Stenotrophomonas, Serratia, MRSA, enterococcus, VRE.
    - Positives: Specimen Source ( Urine ), 11/20/14, Isolate Pseudomonas, S aureuse (MR), enterococcus.
  - Proven or likely organism being treated:** Gram Negatives: Pseudomonas, Serratia, Stenotrophomonas, Klebsiella.
  - Proven or likely site of infection:** Urine.
  - Relevant Information** patient has extensive history of urinary tract infections requiring meropenem due to multiple drug-resistant organisms
- Impression and Plan**
  - Proven Infection:** Continue Meropenem ( Per culture & sensitivities for 10 days, OTHER up to 14 days total duration as clinical condition dictates ).
  - Communication of ASP recommendation:** Minutes to review and communicate: 10 min.
  - Note:** These recommendations are not a medical consult. They are based primarily on a review of the electronic record of the patient's medications and microbiology results as part of the antibiotic microbial stewardship program at Children's Hospital of Pittsburgh of UPMC.

A red circle highlights the "Relevant Information" section under "Review/ Management".


At the bottom of the application window, there is a status bar with "Clinical link on H3PRD GREEMD1 28 December 2015 17:06". The Windows taskbar at the very bottom shows the system tray with the date "5:06 PM 12/28/2015" and various icons.

# Tracking Results to Enhance Quality



- The **PDSA cycle** is shorthand for testing a change by developing a plan to test the change (**Plan**), carrying out the test (**Do**), observing and learning from the consequences (**Study**), and determining what modifications should be made to the test (**Act**)

# Data Warehouse Track Results over Time




Quarterly reports generated automatically from Data warehouse




# Antimicrobial Stewardship At CHP: Where are we now?

- ASP officially in use since January 2009
- Still require ID Pre-approval for selected Abx
- Guidelines for use of “targeted” antimicrobials developed with stakeholders
- Day 3 Auditing for caspofungin, meropenem & vancomycin
- Results reviewed as part of PDSA process on quarterly basis
- The role of ASP established in culture of CHP

# Vancomycin Drug Use



# Meropenem Drug Use




# Guidelines: Another story:

- 5 year old girl worsening abdominal pain, fever and vomiting x 3 days
- Comes to Emergency Department
  - Paucity of bowel sounds
  - Rebound tenderness
  - Diagnosed with ruptured appendicitis
- Laparoscopic surgery performed
- Ertapenem given
- PIC line placed, home on IV antibiotics for two or more weeks

# Appendicitis Guidelines CHP

- Surgical NPs and MDs noted problem with prolonged antibiotic use
- Prolonged use of PIC lines
  - Complications:
    - thrombus, line infection, *C diff*
- Could we do better?
- Met with ID and PharmD
  - Literature review
  - Development of guidelines
  - Buy in from all surgeons

# Appendicitis



- Pre-op Power Plan**
- Admit to
  - Up ad lib
  - NPO
  - VS q 4 hr
  - Strict I & O
  - CBC diff and platelets
  - Electrolytes, BUN, creat (consider BMP)
  - UA
  - HCG, Qual urine (female >= 12 years old)
  - Abdominal Ultrasound Limited (RLQ) OR consider Pelvic Ultrasound for female OR consider CT abdomen and pelvis with contrast if diagnosis is unclear versus 24 hr obs
  - Cefoxitin – IV q 6 hr STAT and on-call OR PCN allergy then:
    - Flagyl IV q 8 STAT and on-call
    - Cipro IV q 12 ISTAT and on-call
  - Morphine IV PRN
  - Consider Consult pain service
  - Dex 5% with 0.45% NaCl + 20 mEq/L KCL
  - Education pre op
  - Education post op

- Non-operative Appendicitis: (Defined as patients with CT findings of perforated appendicitis with discrete abscess)**
- Admit to
  - OOB TID
  - NPO
  - VS q 4 hr
  - Strict I & O
  - Notify MD Temp >= 38.5
  - Dex 5% with 0.45% NaCl + 20 mEq/L KCL
  - Ertapenem IV q 12 hr OR every day (Will transition to PO antibiotics to complete 7 day course of antibiotics when pt. meets discharge criteria.)
  - Morphine IV PRN pain
  - Consult Interventional Radiology for drainage of intraabdominal abscess

- Post-op Appendectomy Power Plan Uncomplicated sub-phase**

- Admit to –
  - Acute appendicitis
  - Gangrenous appendicitis
- OOB TID
- Regular diet
- VS q 4 hr
- Strict I & O
- Notify MD Temp >= 38.5
- Dex 5% with 0.45% NaCl + 20 mEq/L KCL
- Saline lock when tolerating clears
- Oxycodone PRN pain
- Tylenol PRN pain
- Discharge Alive - conditional upon tolerating regular diet, adequate pain control with PO medications and ambulating without difficulty
- Education post op

- Post-op Appendectomy Power Plan Complicated sub-phase**

- Admit to:
  - Perforated appendicitis
  - Perforated appendicitis with abscess
- OOB TID
- NPO, Clear liquids, regular diet
- VS q 4 hr
- Strict I & O
- Notify MD Temp >= 38.5
- NG tube to suction (low continuous) if present
- Ng tube output replacement (1ml/per mL loss, q 4 hr)
- Notify MD urine output < 1 ml/kg/hr x 2 hr
- Foley cath to gravity if present
- Dex 5% with 0.45% NaCl + 20 mEq/L KCL
- Saline lock when tolerating clears
- Ertapenem IV q 12 hr OR every day, will transition to PO antibiotics to complete 5 day course of antibiotics when patient meets discharge criteria
- Morphine IV PRN pain
- Oxycodone PO PRN Pain
- Tylenol PRN pain
- Education post op

# Summary of Guidelines

- Perforated appendicitis
  - At 24 hours: stable and meet d/c criteria
    - Change to oral antibiotics (5 days total Abx)
- Complicated appendicitis
  - When afebrile can be switched to oral Abx for total of 7 days
- Follow up phone call: set questionnaire by pediatric surgical RN
  - Screen positive come back to clinic

# Difference in Length of Stay (LOS) "On" vs "Off" Pathway Post-Operatively

## LOS - Uncomplicated Appendicitis


Consensus for Management Obtained

Powerplan released

"Off Pathway"  
Post-Operatively  
Median LOS:  
**33 hrs**

"On Pathway"  
Post-Operatively  
Median LOS:  
**26 hrs**

LOS Before  
Pathway  
Median  
LOS:  
**36 hrs**




- Actual LOS
- Actual LOS for Patients "On Post-Op Pathway"
- Actual LOS for Patients "Off Post-Op Pathway"
- Median LOS (prior to Pathway)
- Median LOS for Patients "On Post-Op Pathway"
- Median LOS for Patients "Off Post-Op Pathway"



# Difference in LOS "On" vs "Off" Pathway Post-Operatively

## LOS - Complicated Appendicitis


LOS Before Pathway  
Median LOS:  
**155 hrs**




"Off Pathway"  
Post-Operatively  
Median LOS:  
**110hrs**

"On Pathway"  
Post-Operatively  
Median LOS:  
**107 hrs**

## Readmission Rate: Appendicitis Patients



## Administration of Appropriate Pre-Operative Antibiotics (Type & Timing within 60 minutes of Surgical Incision) & Prevalence of Surgical Site Infections



Appropriate pre-op Abx

Decreased Surgical Site Infections

■ Percent of Acute Appendicitis Patients that received appropriate\* antibiotic within 60 minutes of surgical incision  
◆ Percentage of Patients with an SSI

# Summary

- One size doesn't fit all
  - See what works at your institution
  
- CHP using combination
  - Pre-authorization
  - 3 day monitoring
  - Individual guidelines with specific group



# Recognizing the CHP ASP

- Clinical Pharmacy Team
  - Don Berry
  - Kelli Crowley
  - Elizabeth Ferguson
  - Denise Howrie
  - Bill Mcghee
  - Tan Nguyen
  - Carol Vetterly
  - Emily Polischuck
  - Jen Shenk
- Pharmacy
  - Jeff Goff
- Medical Director's Office
  - Ann Thompson
- Infectious Diseases
  - Brian Campfield
  - Toni Darville
  - Michael Green
  - Jim Levin
  - Ling Lin
  - Judy Martin
  - Marian Michaels
  - Andy Nowalk
  - Terri Stillwell
  - John Williams
  - ID Fellows
- GSPH Biostatistics
  - Maria Mori Brooks
  - Jong-Hyeon Jeong
  - Marcia Kurs-Lasky

# Questions?

**need to know** **ANTIBIOTIC RESISTANCE IS NOT COMING IT IS HERE RIGHT NOW**

**need to know** **THE DISCOVERY OF PENICILLIN WAS SO IMPORTANT IT WAS AWARDED A NOBEL PRIZE**

**need to know** **ANTIBIOTICS ARE LOSING THEIR POWER**

**need to know** **ANTIBIOTIC RESISTANCE KNOWS NO GEOGRAPHICAL BOUNDS**

**need to know** **ANTIBIOTICS WON'T MAKE YOUR COLD OR FLU BETTER FASTER**

**need to know** **DON'T ASK FOR ANTIBIOTICS WHEN YOU DON'T NEED THEM**

WINTER IS COMING.NPS.ORG.AU NPS MEDICINEWISE

WINTER IS COMING.NPS.ORG.AU NPS MEDICINEWISE

WINTER IS COMING.NPS.ORG.AU NPS MEDICINEWISE

WINTER IS COMING.NPS.ORG.AU NPS MEDICINEWISE

WINTER IS COMING.NPS.ORG.AU NPS MEDICINEWISE

WINTER IS COMING.NPS.ORG.AU NPS MEDICINEWISE